Resumen
The therapeutic efficiency of combined chemotherapy and gene therapy on human hepatocellular carcinoma HepG2 cells was investigated using double-walled microspheres that consisted of a poly(d,. l-lactic-co-glycolic acid) (PLGA) core surrounded by a poly(l-lactic acid) (PLLA) shell layer and fabricated via the precision particle fabrication (PPF) technique. Here, double-walled microspheres were used to deliver doxorubicin (Dox) and/or chitosan-DNA nanoparticles containing the gene encoding the p53 tumor suppressor protein (chi-p53), loaded in the core and shell phases, respectively. Preliminary studies on chi-DNA nanoparticles were performed to optimize gene transfer to HepG2 cells. The transfection efficiency of chi-DNA nanoparticles was optimal at an N/P ratio of 7. In comparison to the 25-kDa branched polyethylenimine (PEI), chitosan showed no inherent toxicity towards the cells. Next, the therapeutic efficiencies of Dox and/or chi-p53 in microsphere formulations were compared to free drug(s) and evaluated in terms of growth inhibition, and cellular expression of tumor suppressor p53 and apoptotic caspase 3 proteins. Overall, the combined Dox and chi-p53 treatment exhibited enhanced cytotoxicity as compared to either Dox or chi-p53 treatments alone. Moreover, the antiproliferative effect was more substantial when cells were treated with microspheres than those treated with free drugs. High p53 expression was maintained during a five-day period, and was largely due to the controlled and sustained release of the microspheres. Moreover, increased activation of caspase 3 was observed, and was likely to have been facilitated by high levels of p53 expression. Overall, double-walled microspheres present a promising dual anticancer delivery system for combined chemotherapy and gene therapy.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 5149-5162 |
| Número de páginas | 14 |
| Publicación | Biomaterials |
| Volumen | 34 |
| N.º | 21 |
| DOI | |
| Estado | Published - jul 2013 |
Nota bibliográfica
Funding Information:The authors acknowledge the funding support from the National Medical Research Council (NMRC, Singapore) and National Institutes of Health (NIH, USA) under the grant numbers NMRC EDG11may084 and 1R01EB005181 , respectively. Qingxing Xu acknowledges the scholarship support from Agency for Science, Technology and Research (A*STAR, Singapore) for NUS-UIUC Joint Ph.D. Program.
Financiación
The authors acknowledge the funding support from the National Medical Research Council (NMRC, Singapore) and National Institutes of Health (NIH, USA) under the grant numbers NMRC EDG11may084 and 1R01EB005181 , respectively. Qingxing Xu acknowledges the scholarship support from Agency for Science, Technology and Research (A*STAR, Singapore) for NUS-UIUC Joint Ph.D. Program.
| Financiadores | Número del financiador |
|---|---|
| NUS-UIUC | |
| National Institutes of Health (NIH) | 1R01EB005181, NMRC EDG11may084 |
| National Institutes of Health (NIH) | |
| National Institute of General Medical Sciences | R01GM085222 |
| National Institute of General Medical Sciences | |
| Agency for Science Technology and Research | |
| National Medical Research Council Singapore |
ASJC Scopus subject areas
- Biophysics
- Bioengineering
- Ceramics and Composites
- Biomaterials
- Mechanics of Materials
Huella
Profundice en los temas de investigación de 'Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver